ClinVar Miner

Submissions for variant NM_000244.3(MEN1):c.1087_1089GAG[1] (p.Glu364del) (rs1060499971)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000463375 SCV000541175 uncertain significance Multiple endocrine neoplasia, type 1 2016-05-20 criteria provided, single submitter clinical testing This sequence change deletes 3 nucleotides from exon 8 of the MEN1 mRNA (c.1075_1077delGAG). This leads to the deletion of 1 amino acid residue in the MEN1 protein (p.Glu359del) but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (ExAC no frequency). This variant has been reported in an individual affected with parathyroid tumors and pancreatic gastrinoma (PMID: 94633360). Experimental studies have not been reported for this single amino acid deletion; its functional consequence is uncertain. In summary, this is a rare in-frame deletion with uncertain impact on protein function. It has been classified as a Variant of Uncertain Significance.
University of Washington Department of Laboratory Medicine, University of Washington RCV000463375 SCV000611873 benign Multiple endocrine neoplasia, type 1 2018-03-28 criteria provided, single submitter research The MEN1 variant designated as NM_130799.2:c.1075_1077del (p.Glu359del) is classified as benign. In one observed family, multiple family members with the variant are unaffected by the multiple endocrine neoplasia constellation of symptoms, while one individual with a MEN1-associated cancer does not have the variant. Cosegregation analysis of this same observed family was performed using (Rañola et al, 2018, PMID:28965303) and shows a likelihood ratio of 0.0001 to 1 that this allele explains cancer in the family (Thompson, et al., 2003, PMID:12900794). This likelihood ratio indicates strong evidence against pathogenicity as the variant does not co-segregate with reported multiple endocrine neoplasia symptoms in this family. Bayesian analysis integrating all of this data (Tavtigian et al, 2018, PMID: 29300386) gives a <0.1% probability of pathogenicity, which is consistent with a classification of benign. This variant is not predicted to alter MEN1 function or modify cancer risk. A modest (less than 2 fold) increase in cancer risk due to this variant cannot be entirely excluded. This reclassification analysis was performed in conjunction with the family studies project as part of the University of Washington Find My Variant Study.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.